NephroGenex Inc

NephroGenex — Investor Presentation (January 2016)

43 slides from NephroGenex's investor presentation, Jan 7, 2016

  1. Slide 1: Corporate Presentation January 2016

    Corporate Presentation January 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expec

  3. Slide 3: NephroGenex Investment Thesis

    NephroGenex Investment Thesis 3 Developing therapies that target the underlying cause of kidney disease, including diabetic nephropathy, a major unmet medical need with significant healthcare financial burden  Lead product candidate, Pyridorin, has been shown to inhibit formation of advanced glycat

  4. Slide 4: NephroGenex Team

    NephroGenex Team Member Previous Affiliations/Positions Pierre Legault, Chief Executive Officer and President Sanofi-Aventis, President Worldwide Dermatology Eckerd, President Rite Aid, CAO OSI Pharmaceuticals, CFO Prosidion Ltd, CEO Board Member, NPS, Iroko, Tobira, Cyclacel, Forest Labs, others Dr

  5. Slide 5: Scientific Advisory Board

    Scientific Advisory Board Member Affiliations/Positions George L. Bakris, M.D., Hon. DSc ASH Comprehensive Hypertension Center in the Department of Medicine at the University of Chicago, Director and Professor of Medicine American Journal of Nephrology, Editor-in-Chief Up-to-Date, Nephrology and Hyp

  6. Slide 6: NephroGenex Pipeline

    NephroGenex Pipeline Clinical Program Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral dosing that targets the underlying metabolic pathophysiology of diabetic nephrop

  7. Slide 7: Oral Pyridorin – Significant Market Potential

    Oral Pyridorin – Significant Market Potential 7 Diabetic nephropathy progresses from microalbuminuria to macroalbuminuria, then to end stage renal disease (ESRD) and dialysis Estimated 31 million diabetics in the U.S. – 22 million diagnosed, 40% of whom exhibit kidney disease (France, Germany, and U

  8. Slide 8: Pathophysiology of Diabetic Complications

    8 Pathophysiology of Diabetic Complications

  9. Slide 9: Pyridorin – Mechanism of Action

    9 Pyridorin – Mechanism of Action

  10. Slide 10: Preclinical Overview: Pyridoxamine in Models of DN

    10 Other models:  Db/db diabetic mouse model of type 2 diabetic nephropathy 1  KK-A(y)/Ta diabetic mouse model of type 2 diabetic nephropathy 2  Obese Zucker fa/fa rat model of metabolic syndrome early nephropathy 3 Preclinical Overview: Pyridoxamine in Models of DN Control rats +/– pyridoxamine

  11. Slide 11: Clinical Overview: Ph2 Data in Target Ph3 Population

    11 Clinical Overview: Ph2 Data in Target Ph3 Population (Type 2 Diabetes; SCr 1.3-3 mg/dL; Urinary Protein >1200 mg/g Cr; Stable SOC) PYR-210 (52 Wk PIVOTAL Ph 2b Study) PYR-206 PYR-205/207 (26 Wk Phase 2a Studies)

  12. Slide 12: Safety and Tolerability Profile

    12 Preclinical  No toxicity signal in multiple species: ― 13 - 100x human blood level in studies up to 12 months ― no signs of intolerance, toxicity or behavioral changes at doses of 50, 100 and 200 mg/kg in administered once daily through IV infusion for over 30 minutes for seven consecutive days

  13. Slide 13: Pyridorin Development Program

    13 Target Indication:  Prevention or slowing the progression of diabetic nephropathy with type 2 diabetes Program:  Two identical, double-blind Phase 3 studies of 600 patients each Regulatory Agreements:  FDA Special Protocol Assessment  New endpoint of 50% increase in serum creatinine (decrease

  14. Slide 14: Overview of Phase 3 Study - PIONEER

    Objective:  Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population:  Type 2 diabetic subjects  Baseline SCr >1.3 and <3.0 mg/dL (eGFR > 20 ml/min)  Protein/creat

  15. Slide 15: PIONEER Phase 3 Interim Analysis

    PIONEER Phase 3 Interim Analysis 15 DSMB:  Monitoring unblinded safety information on an ongoing basis Interim Analysis 1* (Summer 2016):  Independent biostatistician will undertake an interim analysis when at least 150 subjects have completed a minimum of 12 months on treatment Interim Analysis 2

  16. Slide 16: Summary of Phase 2 Data

    Summary of Phase 2 Data

  17. Slide 17: Phase 2a Studies PYR-206 and PYR-205/7

    PYR-206 (Safety & Tolerability Efficacy not pre-specified) PYR-205/7 (Dose Escalation) Phase 2a Studies - 26 Wk in Type 1 & 2 Diabetic Subjects With Mild/Moderate Nephropathy 17

  18. Slide 18: Phase 2a Studies – Merged Dataset

    18 Phase 2a Studies – Merged Dataset: PYR-206 & PYR205/207 Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB: Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy. Am J Nephrol 2007;27:605–614 SCr change fro

  19. Slide 19: Pivotal Ph 2b Dose-Ranging Study

    19 Pivotal Ph 2b Dose-Ranging Study – 52 wks in Type 2 Diabetic Subjects with Overt Nephropathy (150 mg bd and 300 mg bd) Phase 3 study population agreed with FDA in the SPA

  20. Slide 20: Phase 2b PYR-210 ACEI/ARB and Blood Pressure Medication Changes

    NephroGenex 12 month Phase 2b PYR 210 ACEI/ARB and Blood Pressure Medication Changes Prior to Randomization analysis 20 F re q u e n c y % Run-in Start of Trial - 6 mo F re q u e n c y % - 12 mo Established SOC - 9 mo - 3 mo Start of Trial - 6 mo -12 mo or earlier - 9 mo - 3 mo 60 20 60 20 40 40 Non

  21. Slide 21: Phase 2b PYR-210 Blood Pressure Changes of SOC vs. Non-SOC

    NephroGenex 12 month Phase 2b PYR 210 Blood Pressure Changes of SOC vs. Non-SOC at Screening analysis 21 Patients not on SOC at screening exhibited:  higher starting blood pressures,  more frequent BP medication changes, and  a reduction in BP during the treatment period all of which confounded S

  22. Slide 22: Importance of Stable Standard of Care in DN trials

    22 Importance of Stable Standard of Care in DN trials Note: A decrease in eGFR corresponds to an increase in SCr.

  23. Slide 23: Importance of Stable Standard of Care in DN trials

    23  The FDA is aware of this observed effect of possible acute changes in SCr arising from ACEi/ARB/BP medication changes that could impact the SCr baseline and SCr-based calculated treatment effects.  A pre-specified analysis was included in the Phase 2b Statistical Analysis Plan to evaluate the

  24. Slide 24: PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients

    PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients 24

  25. Slide 25: Post-hoc Analysis of Phase 3 Endpoint in Pivotal Ph 2b Study

    25 Post-hoc Analysis of Phase 3 Endpoint in Pivotal Ph 2b Study

  26. Slide 26: Pyridorin Safety Profile: PYR-210

    Pyridorin has a benign safety profile with the possible exception of a numerical increase in diarrhea and constipation with the higher dose of 300 mg BID Pyridorin Safety Profile: PYR-210 26 Most Reported Adverse Events Most Reported Serious Adverse Events  No meaningful differences between groups

  27. Slide 27: I.V. Pyridorin for Acute Kidney Injury

     Acute kidney injury (AKI) is a serious medical problem that results in substantial morbidity, prolonged hospitalization, increased medical costs, and significant mortality  The major causes of hospital-acquired AKI are decreased renal perfusion during surgery, contrast nephropathy and cancer ther

  28. Slide 28: AKI - Ischemia-reperfusion (I/R) Model

    28 PYR treatment was provided to mice in drinking water starting 72 h prior to injury and continued until sacrificed. AKI - Ischemia-reperfusion (I/R) Model NF = nephrectomy

  29. Slide 29: Exclusivity Patents and New Chemical Entity (NCE)

    No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S.  Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension)  Method of manufacture patent February 2025  NCE - 5 year exclu

  30. Slide 30: NephroGenex Milestones

    NephroGenex Milestones 30 Achieved Expected  Feb-2014 Completion of Initial Public Offering  Mar-2014 Secured CRO  June-2014 Enrolled first patient in PIONEER pivotal Phase 3 trial  Nov-2014 Publication on new endpoint  Nov-2014 Poster presentations at American Society of Nephrology (ASN)  Dec

  31. Slide 31: Financial Snapshot

    Financial Snapshot Cash  As of September 30, 2015, approximately $20.9 million in cash, cash equivalents and investments  Raised an additional $5.0 million of net proceeds from a PIPE in November 2015  Sufficient cash balance to finance operations into mid-2016 NASDAQ: NRX (as of January 5, 2016)

  32. Slide 32: Corporate Summary

    Corporate Summary 32 Developing therapies that target the underlying cause of kidney disease, including diabetic nephropathy, a major unmet medical need with significant healthcare financial burden  Lead product candidate, Pyridorin, has been shown to inhibit formation of advanced glycation end pro

  33. Slide 33: Appendix

    Appendix

  34. Slide 34: Definition: Serum Creatinine and eGFR

    Definition  Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood  Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Compar

  35. Slide 35: PYR-206 – 24 Week Phase 2a Study (50 mg BID)

    35 PYR-206 – 24 Week Phase 2a Study (50 mg BID) PYR-206 Multi-center, randomized, double-blind, placebo- controlled trial to assess safety, tolerability and biological activity:  N = 128  Population: Type 1 or type 2 diabetes ― Baseline SCr ≤ 2.0 mg/dL ― Urinary Protein: Creatinine Ratio (PCR) >30

  36. Slide 36: Phase 2a PYR-206 Post-hoc Analysis

    NephroGenex 6 Month Phase 2a PYR-206 Post-hoc Analysis Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Treatment Effect P value All Patients 65, 63 1.27  0.34 1.33  0.38 0.12  0

  37. Slide 37: PYR-205/207 – 24 Week Phase 2a Study (250 mg BID)

    37 PYR-205/207 – 24 Week Phase 2a Study (250 mg BID) PYR-205/207 Multi-center, randomized, double- blind, dose-escalating, placebo- controlled trial to assess safety, tolerability and biological activity:  N = 84  Population: Type 1 or type 2 diabetes ― SCr ≤ 2.0 mg/dL (PYR- 205); ― SCr >2 mg/dL a

  38. Slide 38: Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis

    NephroGenex 6 Month Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood pressure control Pyridorin at a 250 mg bid dose is well tolerated and slows

  39. Slide 39: PYR-210 – 52 Week Study - Baseline Characteristics

    39 PYR-210 – 52 Week Study - Baseline Characteristics

  40. Slide 40: Phase 2b PYR-210 Pre-Specified Analysis: SOC vs. Non-SOC

    NephroGenex 12 Month Phase 2b PYR-210 Pre-Specified Analysis: SOC at Screening vs. Non-SOC at Screening Patients analysis Type 2 Diabetic Nephropathy Patients With and Without SOC1 at screening – 300 and 150 mg bid 1 SOC: ACEI/ARB therapy and blood pressure control. Patients not on SOC at screening

  41. Slide 41: Primary and Secondary Endpoints

    Primary Endpoints:  Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: ― A serum creatinine (SCr) increase of ≥50

  42. Slide 42: Key Milestone: Dec 2012 NKF/FDA Workshop

    42 Key Milestone: Dec 3-4 2012 NKF/FDA Workshop A doubling of serum creatinine is generally a late event in CKD and takes a long time to develop There is great interest in considering alternative endpoints for clinical trials:  to shorten the duration of clinical trials  to extend their applicatio

  43. Slide 43: Challenges in Developing Treatment for DN

    Challenges in Developing Treatment for DN – Progression of DN is slow and occurs over many years 43

NephroGenex — Investor Presentation (January 2016) on 6ix